抗血管内皮生长因子治疗角膜新生血管的研究进展  

Recent advances in anti-VEGF therapy for corneal neovascularization

作　　者：朱瑞曦 张红[1] 

机构地区：[1]哈尔滨医科大学附属第一医院眼科,黑龙江省哈尔滨市150001

出　　处：《眼科新进展》2014年第7期691-694,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金资助(编号:81201184)~~

摘　　要：角膜新生血管可能会导致视力严重减退,主要与其阻碍光线导致了角膜瘢痕、引起角膜的炎症反应和水肿进而损害损害视力有关。角膜的无血管状态是一个积极主动的过程,角膜能够维持透明性是由于血管生长因子和抗血管生长因子的精确平衡。血管内皮生长因子(vascular endothelial growth factor,VEGF)是最重要的调控介质之一,其上调可以诱发血管生成。而抗VEGF治疗对于许多疾病有效,如年龄相关性黄斑变性、糖尿病视网膜病变等血管生成疾病,同样它们对于角膜新生血管的治疗也具有巨大的潜力,本文就角膜新生血管的抗VEGF治疗现状进行了综述。Corneal neovascularizarion may lead to a profound decline in vision. The abnormal vessels block light lead to corneal scarring, compromise visual acuity, inflammarion and edema. Corneal avascularity is an active process, which is the result of a delicate balance of angiogenic and antiangiogerdc factors. Vascular endothelial growth factor（VEGF） as one of the most mediators of angiogenesis, is up-regulated during neovascularization. While, anti-VEGF agents have efficacy in the treatment of age-related macular degeneration, diabetic retinopathy and other neovascular diseases. This article reviews the recent advances in anti-VEGF therapy for corneal neovascularization.

关 键 词：抗血管内皮生长因子 角膜新生血管 贝伐单抗 雷珠单抗 

分 类 号：R737.31[医药卫生—肿瘤]